LYRA

Lyra Therapeutics, Inc.

Healthcare · Biotechnology

$88.80 sample

-1.13 (-1.26%) 1D

Market cap

$398.1B

Price as of

2026-10-15

Latest filing

8-K · 2026-09-23

Alerts

8

Price$88.80 +12.09% 3M daily closessample

89.9379.22

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 12INSInsider buy: EVP, Operations
Oct 07INSInsider buy: Chief Financial Officer
Sep 30INSInsider sell: 10% owner
Sep 23SECDEF 14A filed
Sep 15INSInsider sell: Chief Financial Officer
Sep 07INSInsider sell: General Counsel
Aug 28INSInsider buy: General Counsel
Aug 20INSInsider sell: 10% owner

Sign up to see the real LYRA record →

Company facts

SEC EDGAR registration

Name: Lyra Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -38sample, -100 to +100
Reporting currency: USD

Who is positioning in LYRA

sample

Insiders: 24 insider transactions over 90 days, net selling, $754.3M
Congress: 3 members traded over 90 days
Institutions · 13F: 33 funds hold $7.9B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$18.2B +12.3% y/y

Q4 2024Q3 2026

Inventory$10.9B +9.0% y/y

Q4 2024Q3 2026

Accounts receivable$8.1B +10.9% y/y

Q4 2024Q3 2026

Total debt$21.9B +7.5% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $145.3B +10.2% 3M
Sample peer B: $83.8B +5.6% 3M
Sample peer C: $149.8B +9.8% 3M
Sample peer D: $111.3B +16.2% 3M
Sample peer E: $323.2B +2.4% 3M